Study of NCR101 for interstitial lung disease
Part of Lungs & breathing clinical trials.
This trial tests an investigational drug called NCR101 to see if it is safe and helps people with interstitial lung disease (a group of conditions that cause lung scarring and breathing problems). It may be an option if your lung disease has been stable and you are already on certain treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with interstitial lung disease, confirmed by a lung scan within the last 6 months.
- If you are on steroids or anti-fibrotic medicines (like pirfenidone or nintedanib), your dose must be stable and you plan to stay on it during the study.
- You have not had severe allergic reactions to the study drug or its ingredients.
- You have not been hospitalized 3 or more times in the past year for sudden worsening of your lung disease.
- You do not need oxygen therapy for more than 15 hours a day and have not used a breathing machine in the past month.
- You have not had infectious pneumonia or needed IV antibiotics in the past month, and you do not have a history of tuberculosis.
- You do not have other serious lung conditions like asthma or significant airway obstruction.
- You are not currently taking high-dose steroids (more than 240 mg of methylprednisolone per day) or using them irregularly.
- If you are of childbearing age, you agree to use effective non-hormonal birth control during the trial and for 6 months after your last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled medication called ICF004 in healthy adults to see if it is safe and how the body processes it. It may help in developing a new treatment for lung conditions.
This trial tests two treatment strategies for people with advanced non-small cell lung cancer who also have interstitial lung disease (a condition causing lung scarring). It aims to find a safe and effective treatment option for this specific group.
This trial tests a single inhaled dose of RJ026 in patients with interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF) or connective tissue disease-related ILD (CTD-ILD). It helps see how the drug moves through the body and if it's safe.
This trial tests a new medication called SC1011 taken twice a day, compared to a placebo, to see if it can help people with IPF. It is for patients who were diagnosed within the last 5 years and have moderate lung function.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
This trial tests an investigational drug called NS-863 for people with pulmonary hypertension (high blood pressure in the lungs) that is caused by interstitial lung disease (scarring of the lungs). The study will check if the drug is safe and effective in improving your condition.
Hear when a new Interstitial Lung Disease (ILD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.